SLC5A2 and hydrops fetalis: Randomised controlled trials have demonstrated that sodium glucose cotransporter 2 inhibitors improve outcomes in individuals with HF,19 but imprecise coding may mask the eligibility of patients to receive these medications, leading to delays in prescription and failure to realise an opportunity to reduce downstream morbidity, mortality and health expenditure.